tetrabenazine has been researched along with Ophthalmoplegia, Progressive Supranuclear in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agid, Y; Duyckaerts, C; Faucheux, B; Hauw, JJ; Herrero, MT; Hirsch, EC; Obeso, JA; Villares, J | 1 |
| Agid, Y; Blin, J; Desnos, C; Javoy-Agid, F; Pierot, L; Raisman, R; Ruberg, M; Scherman, D | 1 |
2 other study(ies) available for tetrabenazine and Ophthalmoplegia, Progressive Supranuclear
| Article | Year |
|---|---|
[125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Brain Diseases; Dopamine Agents; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Immunohistochemistry; Iodine Radioisotopes; Macaca fascicularis; Male; Parkinson Disease; Supranuclear Palsy, Progressive; Tetrabenazine | 1998 |
D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
Topics: Adenylyl Cyclases; Adult; Aged; Benzazepines; Caudate Nucleus; Dopamine Antagonists; Humans; Middle Aged; Parkinson Disease; Putamen; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Reference Values; Spiperone; Supranuclear Palsy, Progressive; Tetrabenazine | 1988 |